Related Experiment Video
Updated: Sep 6, 2025
Detection of Human Leukocyte Antigen Biomarkers in Breast Cancer Utilizing Label-free Biosensor Technology
Published on: March 24, 2015
Coupling Micro-Physiological Systems and Biosensors for Improving Cancer Biomarkers Detection
Virginia Brancato1,2, Rui L Reis3,4, Subhas C Kundu3,4
13B's Research Group, I3Bs-Research Institute on Biomaterials, Biodegradables and Biomimetics, University of Minho, Headquarters of the European Institute of Excellence on Tissue Engineering and Regenerative Medicine, Guimarães, Portugal. virginia.brancato@i3bs.uminho.pt.
Innovative bioengineered systems using microfluidics and biosensors offer new hope for early cancer detection. These advanced tools promise to accelerate biomarker discovery and personalize cancer treatments for improved patient outcomes.
Area of Science:
- Biomedical Engineering
- Oncology
- Molecular Diagnostics
Background:
- Early cancer detection remains a significant clinical challenge.
- Traditional models inadequately replicate the tumor microenvironment for biomarker discovery.
- Noninvasive screening for predictive cancer biomarkers is crucial for saving lives.
Purpose of the Study:
- To explore the potential of microfluidics, biosensors, and 3D cell biology in developing advanced cancer detection methods.
- To assess the progress of cutting-edge technologies towards clinical application.
- To highlight the role of these technologies in advancing precision medicine.
Main Methods:
- Development of micro-physiological bioengineered systems.
- Integration of microfluidics, biosensors, and 3D cell biology.
- Focus on label-free detection and molecular diagnostics.
Main Results:
- Bioengineered systems show promise in improving the discovery of novel cancer biomarkers.
- These technologies can accelerate the development of personalized cancer treatments.
- Point-of-care diagnostic tools are being developed for user-friendly clinical translation.
Conclusions:
- Advanced technologies are paving the way for more effective early cancer detection.
- Microfluidics and biosensors are key enablers for biomarker discovery and personalized medicine.
- Further development is needed to fully integrate these cutting-edge tools into clinical practice.
